

## SAFETY DATA SHEET

### SECTION 1 : IDENTIFICATION

**Product Name:** Adenosine Injection, USP  
**Manufacturer Name:** Fresenius Kabi USA, LLC  
**Address:** Three Corporate Drive  
 Lake Zurich, Illinois 60047  
**General Phone Number:** (847) 550-2300  
**Customer Service Phone Number:** (888) 386-1300  
**Health Issues Information:** (800) 551-7176  
**SDS Creation Date:** January 08, 2009  
**SDS Revision Date:** February 12, 2024

### SECTION 2 : HAZARD(S) IDENTIFICATION

GHS Pictograms:



Signal Word:

DANGER.

GHS Class:

Respiratory sensitisation. category 1.  
 Skin Sensitization. category 1.  
 Specific Target Organ Toxicity - STOT, Single Exposure SE. Category 3.

Hazard Statements:

May cause allergy or asthma symptoms or breathing difficulties if inhaled.  
 May cause an allergic skin reaction.  
 May cause respiratory irritation.

Precautionary Statements:

Avoid breathing dust/fume/gas/mist/vapours/spray.  
 Use only outdoors or in a well-ventilated area.  
 Contaminated work clothing should not be allowed out of the workplace.  
 Wear protective gloves/protective clothing/eye protection/face protection.  
 In case of inadequate ventilation wear respiratory protection.  
 IF ON SKIN: Wash with plenty of water.  
 IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing.  
 Call a POISON CENTER or doctor/physician if you feel unwell.  
 Specific treatment (see ... on this label).  
 If skin irritation or rash occurs: Get medical advice/attention.  
 If experiencing respiratory symptoms: Call a POISON CENTER or doctor/physician.  
 Take off contaminated clothing and wash it before reuse.  
 Store in a well-ventilated place. Keep container tightly closed.  
 Store locked up.  
 Dispose of contents/container in accordance with Local, State, Federal and Provincial regulations.

Emergency Overview:

This product is intended for therapeutic use only when prescribed by a physician. Potential adverse reactions from prescribed doses and overdoses are described in the package insert.

Route of Exposure:

Inhalation Ingestion Eye contact Skin Absorption. Injection.

Potential Health Effects:

Eye:

Contact with eyes may cause irritation.

Signs/Symptoms:

Potential adverse reactions from prescribed doses are described in the package insert and include: Gastrointestinal effects (may include nausea, upset stomach, loss of appetite). nervous system effects (headache, dizziness, light headedness), cardiovascular effects (may include fluctuations in heart rate, changes in blood pressure, chest pain), and respiratory effects (may include shortness of breath, bronchospasms, laryngospasms, respiratory depression). Occupational exposure has not been fully investigated.

Aggravation of Pre-Existing Conditions:

Known hypersensitivity to adenosine and individuals with second or third degree A-V block (except individuals with a functioning artificial pacemaker), and individuals with sinus node disease, such as sick sinus syndrome or symptomatic bradycardia.

### SECTION 3 : COMPOSITION/INFORMATION ON INGREDIENTS

Chemical Name	CAS#	Ingredient Percent	EC Num.
Water for Injection	7732-18-5	Q.S. by Volume	
Adenosine	58-61-7	0.3 %	
Sodium Chloride	7647-14-5	0.9 %	

## SECTION 4 : FIRST AID MEASURES

<b>Eye Contact:</b>	Immediately flush eyes with plenty of water for at least 15 to 20 minutes. Ensure adequate flushing of the eyes by separating the eyelids with fingers. Get immediate medical attention.
<b>Skin Contact:</b>	Immediately wash skin with plenty of soap and water for 15 to 20 minutes, while removing contaminated clothing and shoes. Get medical attention if irritation develops or persists.
<b>Inhalation:</b>	If inhaled, remove to fresh air. If not breathing, give artificial respiration or give oxygen by trained personnel. Seek immediate medical attention.
<b>Ingestion:</b>	If conscious, flush mouth out with water immediately. Call a physician or poison control center immediately. Do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person.
<b>Other First Aid:</b>	For Adverse Event Information, please call (800) 551-7176.

## SECTION 5 : FIRE FIGHTING MEASURES

<b>Flash Point:</b>	Not established.
<b>Flash Point Method:</b>	Not established.
<b>Auto Ignition Temperature:</b>	Not established.
<b>Lower Flammable/Explosive Limit:</b>	Not established.
<b>Upper Flammable/Explosive Limit:</b>	Not established.
<b>Fire Fighting Instructions:</b>	Evacuate area of unprotected personnel. Use cold water spray to cool fire exposed containers to minimize risk of rupture. Do not enter confined fire space without full protective gear. If possible, contain fire run-off water.
<b>Extinguishing Media:</b>	Use alcohol resistant foam, carbon dioxide, dry chemical, or water fog or spray when fighting fires involving this material. Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
<b>Protective Equipment:</b>	As in any fire, wear Self-Contained Breathing Apparatus (SCBA), MSHA/NIOSH (approved or equivalent) and full protective gear.
<b>Hazardous Combustion Byproducts:</b>	Thermal decomposition products may include smoke and toxic fumes. Oxides of carbon, oxides of nitrogen and other organic substances may be formed. Other undetermined low molecular weight hydrocarbon compounds may be released in small quantities depending upon specific conditions of combustion.

## SECTION 6 : ACCIDENTAL RELEASE MEASURES

<b>Personal Precautions:</b>	Evacuate area and keep unnecessary and unprotected personnel from entering the spill area. Avoid personal contact and breathing vapors or mists. Use proper personal protective equipment as listed in Section 8.
<b>Environmental Precautions:</b>	Avoid runoff into storm sewers, ditches, and waterways.
<b>Methods for containment:</b>	Contain spills with an inert absorbent material such as soil, sand or oil dry.
<b>Methods for cleanup:</b>	Absorb spill with inert material (e.g., dry sand or earth), then place in a chemical waste container. After removal, flush spill area with soap and water to remove trace residue.

## SECTION 7 : HANDLING and STORAGE

<b>Handling:</b>	When handling pharmaceutical products, avoid all contact and inhalation of vapor, mists and/or fumes. Use with adequate ventilation. Use only in accordance with directions.
<b>Storage:</b>	Store at controlled room temperature 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature]. Do not refrigerate.
<b>Work Practices:</b>	Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower.
<b>Hygiene Practices:</b>	Wash thoroughly after handling. Avoid contact with eyes and skin. Avoid inhaling vapor or mist.

## SECTION 8: EXPOSURE CONTROLS, PERSONAL PROTECTION

<b>Engineering Controls:</b>	General ventilation is sufficient if this product is being used in a controlled medical setting (clinic, hospital, medical office) for its sole intended parenteral (injection) purpose. Otherwise, use appropriate engineering control such as process enclosures, local exhaust ventilation, or other engineering controls including use of a biosafety cabinet / fume hood to control airborne levels below recommended exposure limits.
<b>Eye/Face Protection:</b>	Chemical splash goggles. Wear a face shield also when splash hazard exist.
<b>Skin Protection Description:</b>	Protective laboratory coat, apron, or disposable garment recommended.
<b>Hand Protection Description:</b>	Wear appropriate protective gloves. Consult glove manufacturer's data for permeability data. Nitrile rubber or natural rubber gloves are recommended.

**Respiratory Protection:** No personal respiratory protective equipment is normally required when this product is being used/administered by a licensed healthcare practitioner (i.e. an end-user such as a clinician / doctor / nurse) for its sole intended parenteral (injection) purpose in a controlled medical setting. The need for respiratory protection will vary according to the airborne concentrations and environmental conditions. A NIOSH approved air-purifying respirator with an organic vapor cartridge or canister may be permissible under certain circumstances. Consult the NIOSH web site (<http://www.cdc.gov/niosh/npptl/topics/respirators/>) for a list of respirator types and approved suppliers.

**Other Protective:** Consult with local procedures for selection, training, inspection and maintenance of the personal protective equipment.

## EXPOSURE GUIDELINES

### SECTION 9 : PHYSICAL and CHEMICAL PROPERTIES

**Physical State:** Liquid solution.  
**Color:** Colorless.  
**Boiling Point:** Not established.  
**Melting Point:** Not established.  
**Solubility:** Soluble. in water.  
**Vapor Density:** Not established.  
**Vapor Pressure:** Not established.  
**Percent Volatile:** Not established.  
**pH:** 4.5 - 7.5  
**Molecular Formula:** Mixture  
**Molecular Weight:** 267.25  
**Flash Point:** Not established.  
**Flash Point Method:** Not established.  
**Auto Ignition Temperature:** Not established.

### SECTION 10 : STABILITY and REACTIVITY

**Chemical Stability:** Stable under normal temperatures and pressures.  
**Hazardous Polymerization:** Not reported.  
**Conditions to Avoid:** No conditions contributing to instability are known to exist for normal handling of this product.

### SECTION 11 : TOXICOLOGICAL INFORMATION

**Teratogenicity:** Pregnancy Category C: Animal reproduction studies have not been conducted with adenosine; nor have studies been performed in pregnant women. As adenosine is a naturally occurring material, widely dispersed throughout the body, no fetal effects would be anticipated. However, since it is not known whether adenosine injection can cause fetal harm when administered to pregnant women, adenosine injection should be used during pregnancy only if clearly needed.

#### **Adenosine :**

**RTECS Number:** AU7175000

**Ingestion:** Oral - Mouse LD50: >20 gm/kg [Details of toxic effects not reported other than lethal dose value]

**Other Toxicological Information:** Intravenous. - Rat TDLo: 249.9 ug/kg/5M [Vascular - BP lowering not characterized in autonomic section]  
Intravenous. - Rat TDLo: 1 mg/kg/1H [Vascular - measurement of regional blood flow]  
Intravenous. - Rat TDLo: 12 mg/kg/12H [Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases Biochemical - Metabolism (Intermediary) - effect on inflammation or mediation of inflammation]  
Intravenous. - Human TDLo: 200 ug/kg [Autonomic Nervous System - sympathomimetic Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical - Metabolism (Intermediary) - Plasma proteins not involving coagulation]  
Intravenous. - Human LDLo: 0.09 mg/kg [Cardiac - pulse rate Vascular - BP lowering not characterized in autonomic section Lungs, Thorax, or Respiration - respiratory depression]  
Intravenous. - Mouse TDLo: 2 mg/kg [Kidney/Ureter/Bladder - changes in blood vessels or in circulation of kidney]  
Intravenous. - Mouse TDLo: 20 mg/kg [Vascular - BP lowering not characterized in autonomic section]  
Subcutaneous - Mouse LD50: 39.6 ug/kg [Details of toxic effects not reported other than lethal dose value]  
Intraperitoneal. - Mouse LD50: 500 mg/kg [Details of toxic effects not reported other than lethal dose value]  
Intraperitoneal. - Rat TDLo: 80 ug/kg [Behavioral - alteration of classical conditioning]  
Intraperitoneal. - Rat TDLo: 80 ug/kg [Brain and Coverings - changes in surface EEG Behavioral - changes in motor activity (specific assay)]  
Intraperitoneal. - Rat TDLo: 2100 mg/kg/21D (intermittent) [Nutritional and Gross Metabolic - weight loss or decreased weight gain]  
Intraperitoneal. - Mouse Cytogenetic analysis: 178 mg/kg

#### **Sodium Chloride :**

**RTECS Number:** VZ4725000

<b>Eye:</b>	Eye - Rabbit Standard Draize test.: 10 mg [Moderate]
<b>Skin:</b>	Administration onto the skin - Rabbit LD50: >10 gm/kg [Details of toxic effects not reported other than lethal dose value] Administration onto the skin - Rabbit Standard Draize test.: 50 mg/24H [mild] Administration onto the skin - Rabbit Standard Draize test.: 500 mg/24H [mild]
<b>Inhalation:</b>	Inhalation - Rat LC50: >42 gm/m3/1H [Details of toxic effects not reported other than lethal dose value]
<b>Ingestion:</b>	Oral - Mouse LD50: 4 gm/kg [Details of toxic effects not reported other than lethal dose value] Oral - Rat LD50: 3000 mg/kg [Details of toxic effects not reported other than lethal dose value]
<b>Other Toxicological Information:</b>	Intravenous. - Mouse LD50: 645 mg/kg [Details of toxic effects not reported other than lethal dose value] Intravenous. - Rabbit LDLo: 1100 mg/kg [Behavioral - convulsions or effect on seizure threshold Behavioral - muscle contraction or spasticity Cardiac - other changes] Intravenous. - Guinea pig LDLo: 300 mg/kg [Details of toxic effects not reported other than lethal dose value] Intravenous. - Mouse TDLo: 2.1 mg/kg [Vascular - other changes Blood - hemorrhage Skin and Appendages - dermatitis, irritative (after systemic exposure)] Intravenous. - Rabbit LDLo: 1.5 mg/kg [Details of toxic effects not reported other than lethal dose value] Intravenous. - Rabbit TDLo: 0.04 mg/kg [Vascular - other changes Blood - hemorrhage Skin and Appendages - dermatitis, irritative (after systemic exposure)] Subcutaneous - Rat LDLo: 3500 mg/kg [Behavioral - irritability] Subcutaneous - Mouse LD50: 3 gm/kg [Details of toxic effects not reported other than lethal dose value] Subcutaneous - Guinea pig LDLo: 2160 mg/kg [Details of toxic effects not reported other than lethal dose value] Subcutaneous - Rabbit TDLo: 0.04 mg/kg [Vascular - other changes Skin and Appendages - dermatitis, irritative (after systemic exposure)] Subcutaneous - Mouse TDLo: 1900 mg/kg [Reproductive - Effects on Embryo or Fetus - fetal death] Subcutaneous - Mouse TDLo: 1900 mg/kg [Reproductive - Specific Developmental Abnormalities - musculoskeletal system] Subcutaneous - Mouse TDLo: 2500 mg/kg [Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)] Subcutaneous - Mouse TDLo: 13440 mg/kg [Reproductive - Fertility - abortion] Intraperitoneal. - Mouse LD50: 2602 mg/kg [Details of toxic effects not reported other than lethal dose value] Intraperitoneal. - Rat LD50: 2600 mg/kg [Details of toxic effects not reported other than lethal dose value] Intraperitoneal. - Rat LDLo: 3.72 gm/kg [Behavioral - tremor Behavioral - convulsions or effect on seizure threshold] Intraperitoneal. - Rat TDLo: 1710 mg/kg [Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - musculoskeletal system] Intraperitoneal. - Rat TDLo: 10 gm/kg [Reproductive - Effects on Newborn - behavioral] Intraperitoneal. - Rat Cytogenetic analysis: 2338 mg/kg

## SECTION 12 : ECOLOGICAL INFORMATION

<b>Ecotoxicity:</b>	No ecotoxicity data was found for the product.
<b>Environmental Stability:</b>	No environmental information found for this product.

## SECTION 13 : DISPOSAL CONSIDERATIONS

<b>Waste Disposal:</b>	Dispose of in accordance with Local, State, Federal and Provincial regulations.
------------------------	---

## SECTION 14 : TRANSPORT INFORMATION

<b>DOT Shipping Name:</b>	Not Regulated.
<b>DOT UN Number:</b>	Not Regulated.

## SECTION 15 : REGULATORY INFORMATION

### Adenosine :

<b>TSCA Inventory Status:</b>	Listed
<b>EINECS Number:</b>	200-389-9
<b>Canada DSL:</b>	Listed

### Sodium Chloride :

<b>TSCA Inventory Status:</b>	Listed
<b>EINECS Number:</b>	231-598-3
<b>Canada DSL:</b>	Listed

## SECTION 16 : ADDITIONAL INFORMATION

### HMIS Ratings:

HMIS Health Hazard: 1  
HMIS Fire Hazard: 0  
HMIS Reactivity: 0  
HMIS Personal Protection: L

SDS Creation Date: January 08, 2009  
SDS Revision Date: February 12, 2024  
SDS Revision Notes: Overall SDS review - no changes.

**Disclaimer:** The information contained herein pertains to this material. It is the responsibility of each individual party to determine for themselves the proper means of handling and using these materials based on their purpose and intended use. Fresenius-Kabi assumes no liability resulting from the use of or reliance upon the information contained in this material safety data sheet. This material safety data sheet does not constitute the guaranty or specifications of the product.

Copyright© 1996-2018 Enviance. All Rights Reserved.